Antibodies are a critical component of the defense arsenal assisting with identifying, capturing, and removing potential threats as well as protecting against future invasions. Our antibodies cover a wide range of disease areas and are tried, tested and trusted by leading laboratories across the world. BBI is at the forefront of innovation and technology and is constantly looking at new production methods to ensure reliable supply.
Our core competencies include a comprehensive suite of reagents with custom development options, lateral flow development, diagnostic manufacturing services and smartphone reader technologies.
Each site follows strict Quality Control and product release protocols, which coupled with effective Quality Assurance processes ensure our products meet stringent product quality, safety and customer requirements.
Innovation is at the heart of our operations. The extensive breadth and depth of our products and services portfolio is testimony to the ongoing investment in our people and facilities.
BBI Solutions has been serving the global diagnostics industry for over 50 years and is the world’s largest independent producer of immuno-diagnostics reagents.
Our antibodies are tried, tested and trusted by leading laboratories worldwide
The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.
Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.
